Concorde Asset Management’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $295K | Sell |
837
-90
| -10% | -$32.1K | 0.14% | 138 |
|
|
2025
Q4 | $304K | Sell |
927
-48
| -5% | -$15.2K | 0.12% | 160 |
|
|
2025
Q3 | $288K | Buy |
+975
| New | +$283K | 0.12% | 157 |
|
|
2025
Q1 | $257K | Sell |
882
-9
| -1% | -$2.66K | 0.14% | 137 |
|
|
2024
Q4 | $232K | Sell |
891
-5
| -0.6% | -$1.48K | 0.12% | 157 |
|
|
2024
Q3 | $289K | Buy |
896
+8
| +0.9% | +$2.62K | 0.16% | 116 |
|
|
2024
Q2 | $277K | Buy |
888
+41
| +5% | +$12K | 0.17% | 109 |
|
|
2024
Q1 | $241K | Sell |
847
-238
| -22% | -$69.6K | 0.16% | 116 |
|
|
2023
Q4 | $249K | Buy |
1,085
+329
| +44% | +$89.6K | 0.17% | 126 |
|
|
2023
Q3 | $203K | Buy |
+756
| New | +$189K | 0.18% | 131 |
|
|
2021
Q3 | – | Sell |
-857
| Closed | -$209K | – | 195 |
|
|
2021
Q2 | $209K | Buy |
857
+2
| +0.2% | +$492 | 0.12% | 180 |
|
|
2021
Q1 | $212K | Sell |
855
-115
| -12% | -$27.4K | 0.12% | 194 |
|
|
2020
Q4 | $224K | Buy |
970
+38
| +4% | +$8.76K | 0.12% | 134 |
|
|
2020
Q3 | $238K | Buy |
932
+37
| +4% | +$9.17K | 0.14% | 154 |
|
|
2020
Q2 | $210K | Buy |
+895
| New | +$204K | 0.18% | 115 |
|
|
2020
Q1 | – | Sell |
-866
| Closed | -$207K | – | 105 |
|
|
2019
Q4 | $207K | Buy |
+866
| New | +$191K | 0.14% | 131 |
|
|
2019
Q3 | – | Sell |
-1,086
| Closed | -$201K | – | 143 |
|
|
2019
Q2 | $201K | Sell |
1,086
-19
| -2% | -$3.4K | 0.12% | 203 |
|
|
2019
Q1 | $212K | Sell |
1,105
-150
| -12% | -$28.6K | 0.14% | 184 |
|
|
2018
Q4 | $243K | Sell |
1,255
-61
| -5% | -$11.9K | 0.21% | 144 |
|
|
2018
Q3 | $273K | Sell |
1,316
-51
| -4% | -$10.1K | 0.27% | 101 |
|
|
2018
Q2 | $252K | Sell |
1,367
-55
| -4% | -$9.73K | 0.29% | 95 |
|
|
2018
Q1 | $244K | Buy |
1,422
+250
| +21% | +$45.9K | 0.3% | 93 |
|
|
2017
Q4 | $204K | Sell |
1,172
-109
| -9% | -$19.3K | 0.26% | 107 |
|
|
2017
Q3 | $237K | Sell |
1,281
-685
| -35% | -$121K | 0.21% | 123 |
|
|
2017
Q2 | $338K | Sell |
1,966
-88
| -4% | -$14.3K | 0.46% | 78 |
|
|
2017
Q1 | $337K | Buy |
2,054
+114
| +6% | +$18.9K | 0.56% | 64 |
|
|
2016
Q4 | $290K | Sell |
1,940
-231
| -11% | -$34.8K | 0.52% | 67 |
|
|
2016
Q3 | $351K | Buy |
2,171
+387
| +22% | +$65.4K | 0.44% | 70 |
|
|
2016
Q2 | $271K | Buy |
+1,784
| New | +$277K | 0.27% | 96 |
|
Other funds holding AMGN
VCM
VPM
Concorde Asset Management's AMGN Position: Q1 2026 in Review
Concorde Asset Management reduced its Amgen (AMGN) stake by 9.7% in Q1 2026, selling an estimated $32.1K and leaving 837 shares worth $295K. The position accounts for 0.14% of the portfolio, ranked #138.
Concorde Asset Management first reported a position in AMGN in Q2 2016 and has held it in 29 quarters since. The position peaked at $351K in Q3 2016. 3,128 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Concorde Asset Management held 837 shares of Amgen worth $295K as of Q1 2026.
- Concorde Asset Management sold 90 Amgen shares in Q1 2026, an estimated $32.1K.
- Amgen made up 0.14% of Concorde Asset Management's portfolio in Q1 2026, its #138 holding.
- Concorde Asset Management first reported a position in Amgen in Q2 2016 and has held it in 29 quarters since.
- Concorde Asset Management's Amgen position peaked at $351K in Q3 2016.
- 3,128 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Concorde Asset Management's 13F filing for Q1 2026, filed 1 Jun 2026.